We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group
Read MoreHide Full Article
For Immediate Release
Chicago, IL – May 25, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bank of America Corp. (BAC - Free Report) , Novo Nordisk A/S (NVO - Free Report) , Novartis AG (NVS - Free Report) , Analog Devices, Inc. (ADI - Free Report) and Sony Group Corp. (SONY - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for B of A, Novo Nordisk and Novartis
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp., Novo Nordisk A/S, and Novartis AG. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Bank of America shares have declined -14.6% over the past year against the Zacks Banks - Major Regional industry's decline of -16.6%. However, the company's first-quarter 2022 results benefited substantially from loan growth and higher rates.
The Zacks analyst believes that the opening of financial centers, enhancement in digital capabilities and cost-saving efforts will likely keep aiding profits. Supported by robust loan growth and the investment banking (IB) pipeline, the company's top line is expected to keep improving.
Bank of America is expected to keep enhancing shareholder value through impressive capital deployments. However, despite the expected rate hikes in 2022, relatively low rates might hurt margins and interest income for some time in the near term. The volatile nature of the trading business is concerning as it might hamper fee income growth.
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+34.2% vs. +20.0%) on the back of one of the broadest diabetes portfolios in the industry. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs is expected to further boost sales.
However, lower realized prices in the Unites States, loss of exclusivity for products and stiff competition are affecting sales. Sales are also being negatively impacted by the COVID-19 pandemic. Also, the supply challenges for Wegovy have hurt the stock. The patent expiry on some of the products in Novo Nordisk's portfolio is concerning too.
Novartis shares have gained +3.7% in the year to date period against the Zacks Large Cap Pharmaceuticals industry's gain of +5.1%. Novartis' performance in the first quarter, in fact, was good as the lagging Sandoz business returned to growth and cardiovascular drug Entresto maintained its stellar performance.
The Zacks analyst believes that drugs like Cosentyx, Entresto, Kesimpta, gene therapy Zolgensma, Kisqali and Leqvio should continue to fuel growth and offset the impact of generic competition. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also aid performance. However, generic competition for key drugs and pipeline setbacks poses concerns.
Other noteworthy reports we are featuring today include Analog Devices, Inc., and Sony Group Corp.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group
For Immediate Release
Chicago, IL – May 25, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bank of America Corp. (BAC - Free Report) , Novo Nordisk A/S (NVO - Free Report) , Novartis AG (NVS - Free Report) , Analog Devices, Inc. (ADI - Free Report) and Sony Group Corp. (SONY - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for B of A, Novo Nordisk and Novartis
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp., Novo Nordisk A/S, and Novartis AG. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Bank of America shares have declined -14.6% over the past year against the Zacks Banks - Major Regional industry's decline of -16.6%. However, the company's first-quarter 2022 results benefited substantially from loan growth and higher rates.
The Zacks analyst believes that the opening of financial centers, enhancement in digital capabilities and cost-saving efforts will likely keep aiding profits. Supported by robust loan growth and the investment banking (IB) pipeline, the company's top line is expected to keep improving.
Bank of America is expected to keep enhancing shareholder value through impressive capital deployments. However, despite the expected rate hikes in 2022, relatively low rates might hurt margins and interest income for some time in the near term. The volatile nature of the trading business is concerning as it might hamper fee income growth.
(You can read the full research report on Bank of America here >>>)
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+34.2% vs. +20.0%) on the back of one of the broadest diabetes portfolios in the industry. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs is expected to further boost sales.
However, lower realized prices in the Unites States, loss of exclusivity for products and stiff competition are affecting sales. Sales are also being negatively impacted by the COVID-19 pandemic. Also, the supply challenges for Wegovy have hurt the stock. The patent expiry on some of the products in Novo Nordisk's portfolio is concerning too.
(You can read the full research report on Novo Nordisk here >>>)
Novartis shares have gained +3.7% in the year to date period against the Zacks Large Cap Pharmaceuticals industry's gain of +5.1%. Novartis' performance in the first quarter, in fact, was good as the lagging Sandoz business returned to growth and cardiovascular drug Entresto maintained its stellar performance.
The Zacks analyst believes that drugs like Cosentyx, Entresto, Kesimpta, gene therapy Zolgensma, Kisqali and Leqvio should continue to fuel growth and offset the impact of generic competition. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also aid performance. However, generic competition for key drugs and pipeline setbacks poses concerns.
(You can read the full research report on Novartis here >>>)
Other noteworthy reports we are featuring today include Analog Devices, Inc., and Sony Group Corp.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.